Dr. Pirow Bekker This is Me

Education

 View all 12 references Web References

1. 1. Osteoporosis: People

   www.amgen-inflammation.com/rhe - [Cached]

   Published on: 4/18/2005   Last Visited: 4/18/2005

   Pirow Bekker has been with Amgen since December 1997 and is Senior Director in Clinical Research. As such, he has been responsible for formulating clinical development strategy, design, and execution of clinical trials. While at Amgen, Pirow has led development teams for several compounds including osteoprotegerin (OPG), AMG 162, ENBREL® (etanercept), and KINERET® (anakinra). Before joining Amgen, Pirow spent seven years at Procter and Gamble Pharmaceuticals where he led clinical development of risedronate, a drug for the treatment of osteoporosis and Paget's disease.
   
   Pirow received his medical degree from the University of Pretoria, South Africa, and a Ph.D. in Molecular and Cell Biology from Pennsylvania State University where he also completed a postdoctoral fellowship in Molecular and Cell Biology.

2. 2. Today's News

   www.prnewswire.com/cgi-bin/sto - [Cached]

   Published on: 10/22/2002   Last Visited: 10/22/2002

   "This study provides evidence that inhibition of the inflammatory protein interleukin-1 slows the progression of RA," said Dr. Pirow Bekker, Amgen senior director of clinical research. "In a one-year study, we found that more patients treated with Kineret had no progression in bone erosions or cartilage degradation than patients treated with placebo. We also saw that the effect of Kineret was evident early, with significant inhibition of disease progression apparent by week 24."
   
   The sBLA is based on the results of a 12-month, double blind, placebo controlled trial. The study results will be presented in a late breaking poster session at the 66th Annual American College of Rheumatology Scientific Meeting in New Orleans.

3. 3. Amgen Files With FDA For Use Of Kineret® To Inhibit Bone And Joint Damage Due To Rheumatoid Arthritis

   www.amgen.com/news/news02/pres - [Cached]

   Published on: 10/22/2002   Last Visited: 1/16/2005

   "This study provides evidence that inhibition of the inflammatory protein interleukin-1 slows the progression of RA," said Dr. Pirow Bekker, Amgen senior director of clinical research.